buthionine sulfoximine and glutathione synthesis resistant human breast cancer cells Cytotoxic effects of glutathione synthesis

Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy

Approximately 90% of patients improve with conservative treatments

These include environmental factors, such as ultraviolet (UV) radiation and environmental pollutants, including ozone and cigarette smoke (115, 116)

Animal-model research has investigated BPC-157 in the context of gastric mucosal protection, intestinal barrier integrity, and gut-lining repair-adjacent signalling